NCT07520006RecruitingPhase 1/2
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 2 Apr 2026
- Start date
- 30 Sept 2026
- Primary completion date
- 31 May 2033
- Lead sponsor
- Nurix Therapeutics, Inc.
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT07520006
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 150
- From 30 Sept 2026 to the primary completion date, 31 May 2033
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
This page is information, not medical advice. Discuss any trial with your doctor.